Could you please provide me with the numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs within the dermatology or gastroenterology departments?
Abatacept (Orencia)
Adalimumab (Humira)
Apremilast (Otezla)
Certolizumab Pegol (Cimzia)
Etanercept (Enbrel)
Etanercept biosimilar (Benepali)
Fumaric Acid Esters N/A
Golimumab (Simponi)
Infliximab (Remicade)
Infliximab biosimilar (Inflectra)
Infliximab biosimilar (Remsima)
Rituximab (MabThera)
Secukinumab (Cosentyx)
Ixekizumab (Taltz)
Tocilizumab (RoActemra)
Ustekinumab (Stelara)
Vedolizumab (Entyvio)

Download response Biologics and biosimilar prescribing. 290617